Vitrafy Life Sciences Limited (ASX:VFY) has released the addresses by Chair Leigh Farrell and Managing Director and CEO Brent Owens, along with the presentation slides delivered at the company's 2026 Annual General Meeting held on 17 November 2026.
Key Points
- Chair Leigh Farrell addressed shareholders for the first time in his role at the 2026 AGM held in Melbourne
- The company completed a $30 million institutional placement in June and a $2 million share purchase plan closed in July
- As at 30 September, the company held approximately $38.3 million in cash and term deposits
- Jan Gielen is appointed to join as Chief Financial Officer on 1 February 2027
- Dr Jeannette Joughin was welcomed to the Board in January, chairing the Remuneration and Nomination Committee
FY26 Transition to Early Commercialisation
According to the Chair's address, FY26 saw Vitrafy transition from research and development to early commercialisation. The Chair cited independently validated scientific achievements, growing partnerships, regulatory progress, and a transition to a U.S.-centred operating model as key developments during the period. The Chair noted that platelet study results with the U.S. Army Institute of Surgical Research, released in May, represented a turning point for the company. The filing states that leading U.S. blood collection organisations are now evaluating the company's ecosystem as a cryopreservation solution.
Capital Raising and Cash Position
The filing discloses that in June the company completed a $30 million institutional placement, followed in July by the closing of a $2 million share purchase plan. The Chair stated the capital raised was directed toward cryopreservation device scale-up, U.S. manufacturing establishment, and scaling up U.S. operations. As at 30 September, the company held approximately $38.3 million in cash and term deposits. The filing notes that costs in the short term will continue to rise as the company invests in validation, manufacturing, and the delivery of initial medical device units.
Board and Executive Leadership Changes
The filing discloses that co-founder Brent Owens completed his first year as Managing Director and CEO, having succeeded Kate Munnings, who continues as a Non-Executive Director. Dr Jeannette Joughin joined the Board in January, bringing more than three decades of senior executive and board experience in biotechnology and medical technology across the United States and Australia. The company also appointed a U.S.-based Chief Operating Officer and Chief Regulatory Officer, alongside a Chief Commercial Officer and Chief Scientific Officer based in Colorado. Jan Gielen is set to join as Chief Financial Officer on 1 February 2027.




Please wait processing your request...